Profile Details

Contact

★★★★★

☆☆☆☆☆

USD 40 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Sarah M.

United Kingdom

USD 40 /hr

Profile Summary

I am an experienced scientist with over 15 years of experience in both academic and industrial settings. I started my career at GlaxoSmithKline where I was a Study Director in Genetic Toxicology within Preclinical Safety Assessment. I completed my PhD in DNA damage response signalling in the Genome Damage and Stability Centre at the University of Sussex. My postdoctoral career began at the Sussex Drug Discovery Centre with a focus on oncology targets. My main area of interest was in targeting DNA repair proteins to identify new therapies for the treatment of cancer.

Subject Matter Expertise

• ★ Biochemistry
• ☆ STEM
• ☆ Molecular Biology
• ☆ Genetics
• ☆ Data Analysis
• ☆ Protein/Enzyme Engineering
• ☆ Research Methodology
• ☆ Technical & Scientific Writing

Services

• Writing
• Consulting
• Product Development

Work Experience

Research Assistant

University of Sussex

July 2004 - July 2012

Associate Scientist

GlaxoSmithKline Research and Development

September 2000 - July 2004

Education

Education details not provided.

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

(2016). A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct . Oncotarget.

(2016). Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2 . The Biochemical journal.

(2014). Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors . Analytical biochemistry.

(2012). Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome . PLoS genetics.

(2011). Mutations in ORC1, encoding the largest subunit of the origin recognition complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome . Nature genetics.

(2009). XLF-Cernunnos promotes DNA ligase IV-XRCC4 re-adenylation following ligation . Nucleic acids research.

(2008). Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling . Nature genetics.

(2007). Chromosome breakage after G2 checkpoint release . The Journal of cell biology.

(2006). ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling . The EMBO journal.

(2006). DNA-PK autophosphorylation facilitates Artemis endonuclease activity . The EMBO journal.

(2006). Identification of a novel motif in DNA ligases exemplified by DNA ligase IV . DNA repair.

(2005). Biophotonic imaging in HO-1.luc transgenic mice: real-time demonstration of gender-specific chloroform induced renal toxicity . Mutation research.

(2003). Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity . Mutagenesis.